Company says it has isolated virus strains for research
Shenzhen Kangtai Biological Products Co has successfully isolated multiple strains of the Delta variant of the coronavirus in a step that could lead to improved vaccines, media reported on Wednesday.
The report by Shenzhen Special Zone Daily quoted a company executive as saying quality requirements for human vaccines will be strictly followed in the evaluation of the isolated strains.
"In response to new challenges in global epidemic prevention and control, Kangtai will fully promote the R&D and industrialization of the vaccine against the coronavirus variant," the executive said, adding that the inactivated COVID-19 vaccine developed by the company and approved for emergency use in China, is still protective and produces a good immune response to a variety of coronavirus variants.
- Pairs of sister cities between China, Central Asian countries exceed 100
- Xi, Central Asian leaders witness inauguration of China-Central Asia cooperation centers, platform
- Xi, Central Asian leaders sign treaty of permanent good-neighborliness and friendly cooperation
- Discover China Program kicks off at BFSU
- Ministry launches job recruitment program in Qingdao
- Xi says China to set up new centers for cooperation with Central Asia
